92 related articles for article (PubMed ID: 22416349)
21. Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).
Elliott MB; Tebbey PW; Pryharski KS; Scheuer CA; Laughlin TS; Hancock GE
J Med Virol; 2004 Jun; 73(2):300-8. PubMed ID: 15122808
[TBL] [Abstract][Full Text] [Related]
22. Preparation and characterization of realgar nanoparticles and their inhibitory effect on rat glioma cells.
An YL; Nie F; Wang ZY; Zhang DS
Int J Nanomedicine; 2011; 6():3187-94. PubMed ID: 22238507
[TBL] [Abstract][Full Text] [Related]
23. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes.
Barnard DL; Hill CL; Gage T; Matheson JE; Huffman JH; Sidwell RW; Otto MI; Schinazi RF
Antiviral Res; 1997 Mar; 34(1):27-37. PubMed ID: 9107383
[TBL] [Abstract][Full Text] [Related]
24. Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines.
Zhao W; Lu X; Yuan Y; Liu C; Yang B; Hong H; Wang G; Zeng F
Int J Nanomedicine; 2011; 6():1569-77. PubMed ID: 21845047
[TBL] [Abstract][Full Text] [Related]
25. Lack of effect of bovine lactoferrin in respiratory syncytial virus replication and clinical disease severity in the mouse model.
Gualdi L; Mertz S; Gomez AM; Ramilo O; Wittke A; Mejias A
Antiviral Res; 2013 Aug; 99(2):188-95. PubMed ID: 23735300
[TBL] [Abstract][Full Text] [Related]
26. [Antiviral activity of nano-realgar against herpes simplex virus Type II in vitro].
Wang D; Wang L; Xu R; Wu X; Li Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1143-1150. PubMed ID: 31857508
[TBL] [Abstract][Full Text] [Related]
27. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
[TBL] [Abstract][Full Text] [Related]
28. Development of a high-throughput replicon assay for the identification of respiratory syncytial virus inhibitors.
Tiong-Yip CL; Plant H; Sharpe P; Fan J; Rich K; Gorseth E; Yu Q
Antiviral Res; 2014 Jan; 101():75-81. PubMed ID: 24246168
[TBL] [Abstract][Full Text] [Related]
29. Enhanced antitumor activity of realgar mediated by milling it to nanosize.
Tian Y; Wang X; Xi R; Pan W; Jiang S; Li Z; Zhao Y; Gao G; Liu D
Int J Nanomedicine; 2014; 9():745-57. PubMed ID: 24516332
[TBL] [Abstract][Full Text] [Related]
30. [Primary respiratory syncytial virus infection in mice].
Zou Y; Huang H; Xu J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Aug; 24(8):484-6. PubMed ID: 11718040
[TBL] [Abstract][Full Text] [Related]
31. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV).
Mata M; Morcillo E; Gimeno C; Cortijo J
Biochem Pharmacol; 2011 Sep; 82(5):548-55. PubMed ID: 21635874
[TBL] [Abstract][Full Text] [Related]
32. A novel inhibitor of respiratory syncytial virus isolated from ethnobotanicals.
Ojwang JO; Wang YH; Wyde PR; Fischer NH; Schuehly W; Appleman JR; Hinds S; Shimasaki CD
Antiviral Res; 2005 Dec; 68(3):163-72. PubMed ID: 16280176
[TBL] [Abstract][Full Text] [Related]
33. Alleviation of respiratory syncytial virus replication and inflammation by fungal immunomodulatory protein FIP-fve from Flammulina velutipes.
Chang YC; Chow YH; Sun HL; Liu YF; Lee YT; Lue KH; Ko JL
Antiviral Res; 2014 Oct; 110():124-31. PubMed ID: 25131377
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding.
Wu JZ; Ho PC
Eur J Pharm Sci; 2006 Sep; 29(1):35-44. PubMed ID: 16824739
[TBL] [Abstract][Full Text] [Related]
35. [Establishment of two-dimensional electrophoresis proteomic profiles of retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells with apoptosis induced by realgar].
Qi J; Zhang M; He PC
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Mar; 31(3):391-6. PubMed ID: 21485086
[TBL] [Abstract][Full Text] [Related]
36. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.
Teng MN; Whitehead SS; Collins PL
Virology; 2001 Oct; 289(2):283-96. PubMed ID: 11689051
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of respiratory syncytial virus by intravenous gamma-globulin].
Li YH; Zhang GC; Xu DL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep; 21(5):640-2. PubMed ID: 16143076
[TBL] [Abstract][Full Text] [Related]
38. [Experimental research on anti-respiratory syncytial virus effect in vitro of earthworm coelomic fluid].
Li F; Wang JH; Zhang JL; Zhong RG; Niu B
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Apr; 24(2):116-8. PubMed ID: 21110430
[TBL] [Abstract][Full Text] [Related]
39. High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors.
Plant H; Stacey C; Tiong-Yip CL; Walsh J; Yu Q; Rich K
J Biomol Screen; 2015 Jun; 20(5):597-605. PubMed ID: 25656237
[TBL] [Abstract][Full Text] [Related]
40. Lovastatin treatment mitigates the pro-inflammatory cytokine response in respiratory syncytial virus infected macrophage cells.
Ravi LI; Li L; Wong PS; Sutejo R; Tan BH; Sugrue RJ
Antiviral Res; 2013 May; 98(2):332-43. PubMed ID: 23523944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
